Skip to main content
Clinical Trials/NCT05598190
NCT05598190
Recruiting
Not Applicable

A577-nm Pro -Yellow Laser In Treatment of Striae Rubra

Al-Azhar University1 site in 1 country18 target enrollmentStarted: September 15, 2022Last updated:
ConditionsStriae Rubra

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
18
Locations
1
Primary Endpoint
dermoscopic change of width of striae rubrae

Overview

Brief Summary

Stretch marks or striae are common skin condition occurring in both genders, but they are more prevalent among women. These are linear dermal scars that are accompanied by epidermal atrophy. They usually occur frequently in numerous physiological and pathological conditions, such as adolescent growth, pregnancy, obesity, Cushing disease, Marfan syndrome, and long-term systemic or topical steroid use. Decreased expression of collagen and fibronectin genes has also been associated with striae.

The pro-yellow laser systems can be used in a wide range of indications such as facial erythema, facial telangiectasia, port wine stain nevus, rosacea, poikilo derma civatte, and Becker's nevus

Some of these indications are clinical lesions in the vascular pattern; some are related to the factors that trigger vascularity, such as vascular endothelial growth factor (VEGF) in etiopathogenesis

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • .Patients diagnosed with striae rubera. .Age groups: at any age. .Sex : ( females).
  • Co-operative patient

Exclusion Criteria

  • Pregnancy .
  • Patient using drugs exacerbating stria as topical or systemic steroid, and patients using other forms of treatment for stria as topical tretinoin, emollients, glycolic acid peel and laser, because that might affect the result of our study.
  • Stria Alba.
  • Skin infection (viral, bacterial or parasitic).
  • Immunosuppressed patients or with history of malignancy or radiation therapy and chronic debilitating diseases and Cushing syndrome.
  • Hypersensitivity to light and intak of photosensitizing drugs.

Outcomes

Primary Outcomes

dermoscopic change of width of striae rubrae

Time Frame: 1 year

dermoscopic photo for width of striae

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Soha Alaa Abdelaal

resident doctor atD dermatology department

Al-Azhar University

Study Sites (1)

Loading locations...

Similar Trials